Antiverse raises funding and demonstrates therapeutic antibody identification with AI-driven drug discovery platform
Summary
7 of these binders were confirmed as antagonists (Figure 2), blocking GPCR activity.GPCRs are a class of cell membrane receptors that play a crucial role in various physiological processes. With over 400 GPCRs linked to over 30 diseases, and only two FDA-approved antibody therapeutics existing for this family of receptors, these assets have significant potential for therapeutic applications.The $3 million investment was received from new investors InnoSpark, AngelHub, Kadmos Capital and Tomorrow Scale, as well as existing investors, Tensor Ventures, Deep Science Ventures, Ed Parkinson and Development Bank of Wales (DBW).Murat Tunaboylu, the co-founder and CEO of Antiverse said:This is the most comprehensive validation of our platform thus far. While identifying antibodies to GPCRs has traditionally been a complex and time-intensive process requiring expensive specialist technology and training, we have demonstrated that Antiverses drug discovery platform can achieve this in a fraction of the time and cost. I would like to thank our investors, this funding will enable us to continue to develop these assets in-house with our academic collaborators.Matt Fates, a board member at Antiverse and partner at InnoSpark commented:To learn more about Antiverse and how we are engineering the future of drug discovery, you can visit our website antiverse.io and follow us on LinkedIn or Twitter.Antiverse was co-founded in 2017 with the goal of engineering the future of drug discovery to change peoples lives. Share it with your network!To learn more about Antiverse and how we are engineering the future of drug discovery, you can visit our website antiverse.io and follow us on LinkedIn and Twitter.